Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wilks, Sharon
NCT06257758: A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors	Recruiting	1/2	165	US	VIO-01	Valerio Therapeutics	Advanced or Metastatic Solid Tumors, Breast Cancer, Recurrent Ovarian Cancer, Prostate Cancer	01/26	12/28
BBI-20233042, NCT06052852: Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies	Recruiting	1/2	147	US	BDC-3042, Cemiplimab, Libtayo, Immune checkpoint inhibitor	Bolt Biotherapeutics, Inc., Regeneron Pharmaceuticals	Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma	03/26	03/28
NCT05511844: Study of ORM-5029 in Subjects with HER2-Expressing Advanced Solid Tumors	Active, not recruiting	1	87	US	ORM-5029	Orum Therapeutics USA, Inc.	HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation	04/25	10/25
Hackmaster, Melissa
TWT-101, NCT04521413: Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies	Recruiting	1/2	170	Canada, US, RoW	CFI-402411, 2411, 402411, Pembrolizumab, Keytruda, pembro	Treadwell Therapeutics, Inc, TIO Discovery Engine	Advanced Solid Malignancies	11/24	12/24
TWT-203, NCT05251714: CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer	Recruiting	1/2	44	US	CFI-402257, 2257, 402257, Fulvestrant, Faslodex	Treadwell Therapeutics, Inc	Advanced Solid Tumor, Breast Cancer	08/25	08/25
NCT03819387: A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer	Completed	1	49	US	NBF-006	Nitto BioPharma, Inc.	Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer	11/23	03/24
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Recruiting	1	321	Europe, US	INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide	Inhibrx Biosciences, Inc	Colorectal Adenocarcinoma, Ewing Sarcoma	06/26	12/26